Raymond James & Associates Xilio Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 38,825 shares of XLO stock, worth $30,671. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,825
Previous 38,825
-0.0%
Holding current value
$30,671
Previous $36,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding XLO
# of Institutions
35Shares Held
12.8MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.61 Million0.93% of portfolio
-
Morgan Stanley New York, NY1.44MShares$1.14 Million0.0% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.14 Million16.6% of portfolio
-
Ghisallo Capital Management LLC Greenwich, CT1.33MShares$1.05 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.15MShares$909,3080.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $21.7M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...